Minerva Neurosciences, Inc (NASDAQ:NERV – Get Free Report) has been assigned an average rating of “Hold” from the four brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $10.33.
A number of research analysts have recently commented on NERV shares. Jefferies Financial Group raised shares of Minerva Neurosciences from a “hold” rating to a “mixed” rating and upped their price objective for the company from $7.50 to $10.00 in a research report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Monday, September 21st. Wall Street Zen downgraded Minerva Neurosciences from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Finally, Zacks Research upgraded Minerva Neurosciences from a “strong sell” rating to a “hold” rating in a research note on Friday, October 9th.
Check Out Our Latest Analysis on Minerva Neurosciences
Minerva Neurosciences Price Performance
Shares of Minerva Neurosciences stock opened at $2.00 on Friday. Minerva Neurosciences has a fifty-two week low of $1.96 and a fifty-two week high of $8.80. The firm has a fifty day moving average price of $2.80 and a two-hundred day moving average price of $4.73. The company has a market cap of $99.66 million, a PE ratio of -0.07 and a beta of 0.09.
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The biopharmaceutical company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($1.46). Analysts expect that Minerva Neurosciences will post -0.70 earnings per share for the current fiscal year.
Institutional Trading of Minerva Neurosciences
A number of hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC increased its holdings in Minerva Neurosciences by 47,614.0% in the 1st quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company’s stock valued at $25,873,000 after buying an additional 4,285,259 shares during the period. Seven Fleet Capital Management LP acquired a new position in shares of Minerva Neurosciences in the 1st quarter valued at $6,855,000. DV Trading LLC acquired a new position in shares of Minerva Neurosciences in the 1st quarter valued at $5,358,000. Bank of New York Mellon Corp bought a new position in shares of Minerva Neurosciences during the 2nd quarter worth about $419,000. Finally, Bank of America Corp DE lifted its holdings in shares of Minerva Neurosciences by 78,272.5% during the 1st quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 39,919 shares during the period. Institutional investors own 34.56% of the company’s stock.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. It focuses on developing treatments for central nervous system disorders and does not have marketed products. The company’s principal drug candidate has been roluperidone, an oral medicine studied for negative symptoms of schizophrenia. The candidate remains investigational; its development has included clinical trials and regulatory review in the United States. Minerva’s earlier research pipeline has also included MIN-301, a biologic candidate studied for Parkinson’s disease.
See Also
- Five stocks we like better than Minerva Neurosciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
